Crossmark

Radiotherapy, tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion chemotherapy of RALOX versus FOLFOX for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score-matching cohort study

Crossref DOI link: https://doi.org/10.1007/s12672-025-02553-9

Published Online: 2025-05-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tan, Hao-yang

Liu, Shuang-quan

Liu, Yan-han

Dai, Guo-hua

Zheng, Jiu-ling

Feng, Hua-guo
Funding

Funding for this research was provided by:

Chongqing Science and Health Joint Traditional Chinese Medicine Project (2025ZYYB017)

Chongqing University Jiangjin Hospital Internal Cultivation Project (2024LCXM002)
License Information

Text and Data Mining valid from 2025-05-10

Version of Record valid from 2025-05-10
More Information

Article History

Received: 10 February 2025

Accepted: 2 May 2025

First Online: 10 May 2025

Declaration

:

: This study adhered to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Chongqing University Jiangjin Hospital (KY20240812-001). This study was registered in the Chinese Clinical Trial Registry (ChiCTR2500095127). The patient's informed consent form before treatment complied with the requirements of the Institutional Review Committee of Chongqing University Jiangjin Hospital. Informed consent was obtained from all individual participants included in the study.

: The authors have no relevant financial or non-financial interests to disclose.

Document is current

Any future updates will be listed below